Completed

FIBROCHIRFibrocytes' Role in Bronchial Remodelling of COPD

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to screen and observe the increase in the number of fibrocytes, both in the blood and around the bronchial area, at various stages of Chronic Obstructive Pulmonary Disease (COPD), comparing the results to healthy control subjects.

What is being tested

analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients

+ analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients

+ analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients

Biological
Who is being recruted

Chronic Disease+6

+ Lung Diseases

+ Lung Diseases, Obstructive

Over 40 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Screening Study

Placebo-Controlled
Interventional
Study Start: April 2013
See protocol details

Summary

Principal SponsorUniversity Hospital, Bordeaux
Last updated: June 9, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 10, 2013

Actual date on which the first participant was enrolled.

Chronic Obstructive Pulmonary Disease (COPD) is a lung condition where the airways become damaged and thickened, making it hard to breathe. This damage is often caused by ongoing inflammation. The role of specific cells called fibrocytes in this process is not well understood, even though they are known to contribute to similar issues in other lung diseases. This study aims to explore the involvement of fibrocytes in COPD, focusing on individuals at different stages of the disease compared to healthy subjects. Understanding this could provide valuable insights into the progression of COPD and potentially lead to improved treatment strategies. The study involves analyzing the number and distribution of fibrocytes in the blood and around the airways of COPD patients. By comparing these findings with those from healthy individuals, researchers hope to identify any patterns or trends. The primary outcome of the study is to determine if there is an increase in the number of fibrocytes as the severity of COPD progresses. This information could shed light on the role these cells play in the development and worsening of COPD.

NCT01692444
Principal SponsorUniversity Hospital, Bordeaux
Last updated: June 9, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

50 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Screening Study

Screening studies test new methods to find diseases or risk factors early—before any symptoms appear. This helps catch health issues sooner, when they may be easier to treat.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 40 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Chronic DiseaseLung DiseasesLung Diseases, ObstructivePathologic ProcessesRespiratory Tract DiseasesPathological Conditions, Signs and SymptomsDisease AttributesFibrosisPulmonary Disease, Chronic Obstructive

Criteria

5 inclusion criteria required to participate
COPD group: diagnostic of COPD and differentiation of the stage from 1 to 4 according to the GOLD guidelines

Control group: subjects with normal lung function testing and no chronic symptoms (cough or expectoration). Subjects will be separated in 2 groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex

Male or female aged more than 40 yr

Patient needed a thoracic surgery such as lobectomy for cancer or lung transplantation or lung reduction volume surgery

Show More Criteria

5 exclusion criteria prevent from participating
Asthma, lung fibrosis or idiopathic pulmonary hypertension

Chronic viral infections (hepatitis, HIV)

Pregnant woman or breastfeeding

Subject included for cancer surgery with a Pn0 diagnosis not confirmed after the intervention

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

33.333% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
15 patients with COPD from 1 to 4 according to the GOLD 2011

Group II

Placebo
15 patients without COPD and no smoking history

Group III

Active Comparator
15 patients without COPD but a smoking history

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

University hospital of Bordeaux, Hôpital du Haut Lévêque

Pessac, FranceOpen University hospital of Bordeaux, Hôpital du Haut Lévêque in Google Maps
CompletedOne Study Center